Myricx Bio Further Strengthens its Clinical Team and US Presence with the Appointment of David Ellis as VP, Regulatory Affairs

London, UK, 17 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of David Ellis, PhD, in the newly created position of VP, Regulatory Affairs, based in the USA.

David joins Myricx from ADC Therapeutics where he served for over a decade as Vice President, Head of Regulatory Affairs and brings over 27 years of experience in regulatory affairs working for a range of pharma and biotech companies. Previously, he was at Aptalis Pharma where he held the role of Vice President of Global Regulatory Affairs and at Cephalon as its Senior Director of Regulatory Affairs. Earlier roles include independent consultancy and Assistant Vice President in Global Regulatory Affairs at Pfizer and Wyeth Research.

David holds a Ph.D. in Molecular Biology from the University of Nottingham.

Steen Lisby, MD, DMSc at Myricx Bio said, “We are delighted to welcome David to the Myricx team. With several of our N-myristoyltransferase inhibitor (NMTi)-ADC programs progressing towards clinical development and having nominated our lead development candidate, we expect to enter human clinical trials in 2026. David’s extensive global regulatory and ADC expertise will be crucial in driving our regulatory strategies at this pivotal time.”

David Ellis, PhD, VP, Regulatory Affairs at Myricx Bio said, “It’s an exciting time to join Myricx as it advances its programs towards clinical development. With my background in the ADC space and my industry experiences in regulatory affairs, I look forward to using my expertise and working with the Myricx team to further develop and implement plans to support the clinical development and regulatory submissions of its NMTi-ADC drug candidates.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing, Myricx has moved to dedicated facilities in London and expanded its leadership, clinical and R&D teams. David is Myricx’s second US-based team member, following the appointment of Penny Fatato as Global Head of Clinical Operations in August, reflecting its growth ambitions. Myricx plans further appointments in the future in the UK and USA.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a private biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658